İlker Taşdemir

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Anders Widmark, Olbjørn Klepp, Arne Solberg et al. · The Lancet · 2008 · 863 citations · Full text

Endocrine Oncology, Urology, Radiation Medicine +8

BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6

Peter Iversen, Jan‐Erik Johansson, Pär Lodding et al. · The Journal of Urology · 2004 · 99 citations

5-Year Outcome of a Randomized Prospective Study Comparing bacillus Calmette-Guérin with Epirubicin and Interferon-α2b in Patients with T1 Bladder Cancer

Tammer Hemdan, Robert Johansson, Staffan Jahnson et al. · The Journal of Urology · 2013 · 51 citations

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Peter Iversen, Jan‐Erik Johansson, Pär Lodding et al. · Scandinavian Journal of Urology and Nephrology · 2006 · 42 citations

Early Prostate Cancer, Urology, Oncology +14

Reproducibility and Prognostic Value of WHO1973 and WHO2004 Grading Systems in TaT1 Urothelial Carcinoma of the Urinary Bladder

Ok Målfrid Mangrud, Rune Waalen, Einar Gudlaugsson et al. · PLoS ONE · 2014 · 42 citations · Full text